IDH-mutant grade 2 or 3 astrocytoma

Clinical trials for IDH-mutant grade 2 or 3 astrocytoma explained in plain language.

Never miss a new study

Get alerted when new IDH-mutant grade 2 or 3 astrocytoma trials appear

Sign up with your email to follow new studies for IDH-mutant grade 2 or 3 astrocytoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New drug aims to keep brain tumors at bay after standard therapy

Disease control Recruiting now

This phase 3 trial tests whether the drug vorasidenib can delay tumor progression in people with IDH-mutant grade 2 or 3 astrocytoma after they finish initial chemoradiotherapy. About 468 participants will receive either vorasidenib or a placebo daily. The main goal is to see if …

Matched conditions: IDH-MUTANT GRADE 2 OR 3 ASTROCYTOMA

Phase 3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control

Last updated Sep 12, 2026 00:00 UTC

IDH-mutant grade 2 or 3 astrocytoma

Get alerted when new IDH-mutant grade 2 or 3 astrocytoma trials appear

New drug aims to keep brain tumors at bay after standard therapy